Home World News Pembrolizumab Plus Weekly Paclitaxel, With Or Without Bevacizumab, Improves OS in Patients... World News Pembrolizumab Plus Weekly Paclitaxel, With Or Without Bevacizumab, Improves OS in Patients With Platinum-Resistant Recurrent Ovarian Cancer By Ogkologos - April 23, 2026 327 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENGOT-ov65/KEYNOTE-B96 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Contact X-ray Brachytherapy Dose Escalation Increases the Organ Preservation Rate in... November 29, 2024 Resilience Isn’t About Bouncing Back March 8, 2021 ESMO Asia Virtual Congress 2020, 20-22 November October 26, 2020 Can Cooking With Nonstick Cookware Increase Your Cancer Risk? May 16, 2023 Load more HOT NEWS Plasma Lipid Biomarker PCPro Associated with Shorter OS and Earlier Clinical... Cancer Research UK’s charity Christmas cards now available Preparing for your COVID-19 Vaccine: What to Ask your Provider How the Cancer Community Can Help Close the Care Gap This...
